Tag: Actos
Pioglitazone Use Linked to Reduced Dementia Risk in T2DM
Reduction in risk was greatest for those with history of ischemic heart disease or stroke
Pioglitazone Has Limited Effect in Lipoatrophic Diabetes
Slight liver function improvement seen in lipoatrophic diabetes induced by juvenile dermatomyositis
Greater Benefit for Pioglitazone in High-Risk Patients Post Stroke
Patients at higher risk for stroke or MI derive greater benefit from pioglitazone versus low-risk patients
Exenatide, Pioglitazone Effective for Poorly Controlled T2DM
Findings in patients with long-standing poorly controlled type 2 diabetes on metformin, sulfonylurea
Pioglitazone Improves Whole-Body Aerobic Capacity in MetS
Improvements in intramyocellular lipid content, skeletal muscle high-energy phosphate metabolism
Pioglitazone Cuts Diabetes Risk After Ischemic Stroke, TIA
Findings for patients with recent ischemic stroke/TIA and insulin resistance, but no history of diabetes
Long-Term Pioglitazone Safe, Effective for NASH, T2DM
Safe and effective for patients with prediabetes or type 2 diabetes and nonalcoholic steatohepatitis
CYP2C8, SLCO1B1 Variants Impact Response to Rosiglitazone
Genetic variants have clinical impact on response to rosiglitazone, but not pioglitazone
Pioglitazone Linked to Increased Risk of Bladder Cancer
Duration- and dose-response associations for pioglitazone; no correlation for rosiglitazone
ASA: Pioglitazone After Stroke, TIA Helpful in Insulin Resistance
Linked to reduction in risk of stroke, myocardial infarction in patients with insulin resistance
